Mostrar el registro sencillo del ítem

dc.contributor.authorEguren, Manuel
dc.contributor.authorAlvarez Fernandez, Monica 
dc.contributor.authorGarcía, Fernando
dc.contributor.authorLópez-Contreras, Andrés J
dc.contributor.authorFujimitsu, Kazuyuki
dc.contributor.authorYaguchi, Hiroko
dc.contributor.authorLuque-García, José Luis
dc.contributor.authorYamano, Hiroyuki
dc.contributor.authorFernandez-Capetillo, Oscar 
dc.contributor.authorMalumbres Martinez, Marcos 
dc.contributor.authorMunoz, Javier 
dc.date.accessioned2020-11-23T11:47:39Z
dc.date.available2020-11-23T11:47:39Z
dc.date.issued2014-02-27
dc.identifier.citationCell Rep. 2014 ;6(4):670-83.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11399
dc.description.abstractThe Anaphase-promoting complex/cyclosome (APC/C) cofactor Cdh1 modulates cell proliferation by targeting multiple cell-cycle regulators for ubiquitin-dependent degradation. Lack of Cdh1 results in structural and numerical chromosome aberrations, a hallmark of genomic instability. By using a proteomic approach in Cdh1-null cells and mouse tissues, we have identified kinesin Eg5 and topoisomerase 2α as Cdh1 targets involved in the maintenance of genomic stability. These proteins are ubiquitinated and degraded through specific KEN and D boxes in a Cdh1-dependent manner. Whereas Cdh1-null cells display partial resistance to Eg5 inhibitors such as monastrol, lack of Cdh1 results in a dramatic sensitivity to Top2α poisons as a consequence of increased levels of trapped Top2α-DNA complexes. Chemical inhibition of the APC/C in cancer cells results in increased sensitivity to Top2α poisons. This work identifies in vivo targets of the mammalian APC/C-Cdh1 complex and reveals synthetic lethal interactions of relevance in anticancer treatments.es_ES
dc.description.sponsorshipWe thank Angeles Almeida, Thomas U. Mayer, William T. Beck, Anthony A. Hyman, Jan-Michael Peters, Eusebio Manchado, and Scott Lowe for reagents. M. E., A.J.L.-C., and M.A.-F. were supported by the Spanish Ministry of Education, Culture and Sports, the AECC Scientific Foundation, and the EU-PEOPLE programme, respectively. Work in the O.F.-C. laboratory was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2011-23753), the Association for International Cancer Research (120229), the Howard Hughes Medical Institute, and the European Research Council (ERC-210520). Work in the H.Y. laboratory was funded by grants from Marie Curie Cancer Care and Cancer Research UK. Work in M.M.'s laboratory was funded by grants from the Foundation Ramon Areces, MINECO (SAF2012-38215), the OncoCycle Programme (S2010/BMD-2470) from the Comunidad de Madrid, and the European Union Seventh Framework Programme (MitoSys project; HEALTH-F5-2010-241548).es_ES
dc.language.isoenges_ES
dc.publisherCell Press es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAnimals es_ES
dc.subject.meshAntigens, Neoplasm es_ES
dc.subject.meshBinding Sites es_ES
dc.subject.meshCdh1 Proteins es_ES
dc.subject.meshDNA Topoisomerases, Type II es_ES
dc.subject.meshDNA-Binding Proteins es_ES
dc.subject.meshGenomic Instability es_ES
dc.subject.meshHEK293 Cells es_ES
dc.subject.meshHeLa Cells es_ES
dc.subject.meshHumans es_ES
dc.subject.meshKinesin es_ES
dc.subject.meshMice es_ES
dc.subject.meshProtein Binding es_ES
dc.subject.meshProteome es_ES
dc.subject.meshPyrimidines es_ES
dc.subject.meshThiones es_ES
dc.subject.meshTopoisomerase II Inhibitors es_ES
dc.subject.meshUbiquitination es_ES
dc.subject.meshXenopus es_ES
dc.titleA synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID24508461es_ES
dc.format.volume6es_ES
dc.format.number4es_ES
dc.format.page670-83es_ES
dc.identifier.doi10.1016/j.celrep.2014.01.017es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderHoward Hughes Medical Institute 
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.contributor.funderFundación Ramón Areces 
dc.contributor.funderComunidad de Madrid (España) 
dc.contributor.funderUnión Europea 
dc.contributor.funderWorldwide Cancer Research 
dc.contributor.funderCancer Research UK (Reino Unido) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.celrep.2014.01.017es_ES
dc.identifier.journalCell reportses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de División Celular y Cánceres_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómicaes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Proteómicaes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2011-23753es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2012-38215es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/FP7/210520es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/S2010/BMD-2470es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/HEALTH-F5-2010-241548es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional